Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Prostatic Neoplasms × testosterone enanthate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Castration Resistant Metastatic Prostate Cancer 2 Uterine Cervical Neoplasms 1 Prostatic Neoplasms 1 Neoplasms 1 Multiple Endocrine Neoplasia Type 1 1 Fatigue 1 Castration-Resistant Prostate Carcinoma 1 Carcinoma, Squamous Cell 1 Cachexia 1

Interventions

Docetaxel 250 Prednisone 205 enzalutamide 152 Leuprolide 149 Radiotherapy 141 Abiraterone Acetate 133 Magnetic Resonance Spectroscopy 128 Goserelin 113 bicalutamide 111 Androgen Antagonists 94 Radiosurgery 92 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 90 apalutamide 69 gallium 68 PSMA-11 63 Specimen Handling 62 abiraterone 61 Radiation 50 Gonadotropin-Releasing Hormone 50 darolutamide 49 cabazitaxel 46 Triptorelin Pamoate 44 Brachytherapy 44 pembrolizumab 42 Zoledronic Acid 42 Estramustine 41 Carboplatin 41 Biopsy 40 luprolide acetate gel depot 39 Standard of Care 38 Pluvicto 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06594926 2025-11-26

WOMBAT

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡